| Health / Medical Topics |
HDAC Inhibitor CXD101
A novel histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. Although the exact therapeutic mechanism of action for CXD101 is not known, oral administration of this agent should inhibit the catalytic activity of HDAC, which results in an accumulation of highly acetylated histones, followed by the induction of chromatin remodeling and an altered pattern of gene expression. HDAC, a family of enzymes upregulated in many tumor types, deacetylates chromatin-associated histone proteins. (NCI Thesaurus)
YOU MAY ALSO LIKE
An orally bioavailable, second-generation hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity. HDAC inhibitor CHR-3996 inhibits HDAC, resulting in…
A hydroxamic acid-derived histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. CHR-2845 inhibits HDAC leading to an accumulation of highly acetylated histones,…
A histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. CG200745 inhibits the catalytic activity of HDAC, resulting in an accumulation of highly…
An orally bioavailable benzamide and inhibitor of human class I histone deacetylases (HDACs) isoenzymes 1, 2 and 3, with potential antineoplastic…
A substance that causes a chemical change that stops tumor cells from dividing. HDAC inhibitors are being studied in the treatment of…
An enzyme that removes a small molecule called an acetyl group from histones (proteins found in chromosomes). This changes the way the…
